Trial · NCT07126561
Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
NCT07126561, Phase 2, Not yet recruiting, University of Chicago
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers. Trials, record NCT07126561. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07126561
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
- NCT number
- NCT07126561
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 43 participants, estimated
- Lead sponsor
- University of Chicago
- Conditions
- HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
- Interventions
- Trastuzumab Deruxtecan
- First posted
- 2025-08-17
- Last updated
- 2026-01-08
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate | 12 months | The overall response rate (ORR) of participants with an Eastern Cooperative Oncology Group performance status (PS) of 2 who receive single-agent trastuzumab deruxtecan as determined by the treating investigator using RECIST 1.1. |
| Secondary | Percentage of Study Participants with Toxic Side Effects in Response to Trastuzumab Deruxtecan | 12 months | Percentage of subjects with treatment-emergent grade 3-4 toxicities, defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
| Secondary | Overall Survival | 12 months | Overall survival defined as the time from Day 1 of administering trastuzumab deruxtecan (Enhertu) to death from any cause. |
| Secondary | Progression Free Survival | 12 months | Progression free survival defined as the time from Day 1 of administering trastuzumab deruxtecan (Enhertu) until the criteria for disease progression is met as determined by the treating investigator using RECIST 1.1 or death as a result of any cause. |
| Secondary | Disease Control Rate | 12 months | Disease control rate defined as the proportion of participants with RECIST 1.1-based progressive disease, complete response and stable disease divided by the total number of evaluable participants. |
| Secondary | Duration of Response | 12 months | Duration of response defined as the time from disease response to progression or death. This will only calculated for the participants with response. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07126561
GET https://conductscience.org/api/trials/v1/NCT07126561/registered